"Institute of Phage Industry" Unveiling Ceremony, Jointly Crafting a New Chapter in Antibacterial Research
On October 26, 2023, Shandong New Line Biological Technology Co., Ltd. (hereinafter referred to as New Line) achieved another success as the "Institute of Phage Industry" unveiling ceremony was successfully held. This marks a significant milestone for New Line, adding robust momentum to its development, and showcasing its unstoppable growth.
Professor Wang Ran, Vice President of the Jiangsu Academy of Agricultural Sciences, Dr. Sun Lichang, Associate Researcher, and leaders from various sectors attended the unveiling ceremony of the "Institute of Phage Industry" to witness this glorious moment together.
The Institute of Phage Industry was jointly established by the Jiangsu Academy of Agricultural Sciences and Shandong New Line Biological Technology Co., Ltd. New Line, relying on the Jiangsu Academy of Agricultural Sciences and the International Phage Research Center, has formed a research team consisting mainly of more than 30 doctoral and master's degree holders. The company has been focusing on the research and development of bacteriophage products as alternatives to antibiotics, providing solutions for the healthy development of bacterial diseases in China's livestock, agriculture, and food industries. Under the leadership of Chairman Wang Guoqiang, New Line has consistently achieved breakthroughs, dedicated to providing quality and innovative products for the prevention and control of bacterial diseases. The success of this unveiling ceremony signifies another milestone in New Line's development in the field of phage research, further strengthening its collaboration with domestic and international research institutions to actively promote the in-depth development of phage research.
Bacteriophages, as viruses that attack bacteria, have broad applications in the field of biotechnology. Bacteriophage therapy, as an emerging alternative to antibiotics, is of great significance in addressing antibiotic resistance in animal sources. Under the influence of antibiotic restrictions and environmental protection policies, the research and development of bacteriophages continue to rise, indicating promising prospects for antibiotic reduction and replacement. The future market size of bacteriophage therapy is mainly attributed to three factors: (1) Significant effectiveness - as a biological product that lyses bacteria, bacteriophage therapy shows better treatment effects against drug-resistant bacterial infections; (2) Antibiotic replacement - bacteriophage therapy has a clear advantage over antibiotic therapy and is expected to replace antibiotics as a new type of bactericidal drug, with a vast market space; (3) Increasing demand for human use - the number of malignant tumor patients in China is increasing year by year, and it is estimated that by 2022, the number of new cancer cases in China will exceed 5 million, driving the growth in demand for anti-infective and bactericidal drugs.
The widespread application of New Line's bacteriophage products not only enhances the production level of the aquaculture industry but also effectively reduces the use of antibiotics and disinfectants. It is estimated that over the past three years, bacteriophage products have helped the aquaculture industry reduce the use of antibiotics and disinfectants by more than 100 tons, thereby improving the profitability of aquaculture and the safety level of animal-derived food.
The successful hosting of this unveiling ceremony signifies that New Line has taken a solid step in scientific innovation and achievement transformation, laying a solid foundation for the company's future development. Let us look forward together to the unstoppable journey of "New Line" and its brilliant achievements in the future!
Professor Wang Ran, Vice President of the Jiangsu Academy of Agricultural Sciences, Dr. Sun Lichang, Associate Researcher, and leaders from various sectors attended the unveiling ceremony of the "Institute of Phage Industry" to witness this glorious moment together.
The Institute of Phage Industry was jointly established by the Jiangsu Academy of Agricultural Sciences and Shandong New Line Biological Technology Co., Ltd. New Line, relying on the Jiangsu Academy of Agricultural Sciences and the International Phage Research Center, has formed a research team consisting mainly of more than 30 doctoral and master's degree holders. The company has been focusing on the research and development of bacteriophage products as alternatives to antibiotics, providing solutions for the healthy development of bacterial diseases in China's livestock, agriculture, and food industries. Under the leadership of Chairman Wang Guoqiang, New Line has consistently achieved breakthroughs, dedicated to providing quality and innovative products for the prevention and control of bacterial diseases. The success of this unveiling ceremony signifies another milestone in New Line's development in the field of phage research, further strengthening its collaboration with domestic and international research institutions to actively promote the in-depth development of phage research.
Bacteriophages, as viruses that attack bacteria, have broad applications in the field of biotechnology. Bacteriophage therapy, as an emerging alternative to antibiotics, is of great significance in addressing antibiotic resistance in animal sources. Under the influence of antibiotic restrictions and environmental protection policies, the research and development of bacteriophages continue to rise, indicating promising prospects for antibiotic reduction and replacement. The future market size of bacteriophage therapy is mainly attributed to three factors: (1) Significant effectiveness - as a biological product that lyses bacteria, bacteriophage therapy shows better treatment effects against drug-resistant bacterial infections; (2) Antibiotic replacement - bacteriophage therapy has a clear advantage over antibiotic therapy and is expected to replace antibiotics as a new type of bactericidal drug, with a vast market space; (3) Increasing demand for human use - the number of malignant tumor patients in China is increasing year by year, and it is estimated that by 2022, the number of new cancer cases in China will exceed 5 million, driving the growth in demand for anti-infective and bactericidal drugs.
The widespread application of New Line's bacteriophage products not only enhances the production level of the aquaculture industry but also effectively reduces the use of antibiotics and disinfectants. It is estimated that over the past three years, bacteriophage products have helped the aquaculture industry reduce the use of antibiotics and disinfectants by more than 100 tons, thereby improving the profitability of aquaculture and the safety level of animal-derived food.
The successful hosting of this unveiling ceremony signifies that New Line has taken a solid step in scientific innovation and achievement transformation, laying a solid foundation for the company's future development. Let us look forward together to the unstoppable journey of "New Line" and its brilliant achievements in the future!
